The administration of antenatal corticosteroids is an established treatment to prevent neonatal respiratory distress syndrome, for which additional effects on extrapulmonary organs are well documented. 1, 2 In addition to pulmonary immaturity, preterm infants often manifest hypotension and commonly receive vasopressors and/or volume expanders. In ϳ10% of sick preterm infants, plasma cortisol concentrations are undetectable. 3, 4 Recent case reports have demonstrated a positive effect of corticosteroids with regard to increasing blood pressure (BP) in very preterm infants (Ͻ1000 gm) with hypotension resistant to vasopressors and volume expanders. [5] [6] [7] [8] Moreover, in extremely preterm infants (23 to 27 weeks' gestation) antenatal corticosteroids have been associated with a decreased need for BP support during the first 2 days after birth. 9 This study focuses on the first 24 hours of life and aims to determine whether there are differences in arterial BP between a broad population of low birth weight preterm infants born to mothers treated with corticosteroids and infants born to untreated mothers. The study was designed to test the following hypotheses: (1) infants born to steroid-treated mothers will have a higher mean arterial BP during the first 24 hours after birth than infants born to untreated mothers; (2) the effects of antenatal corticosteroids on neonatal BP will be greater in the lowest birth weight categories; and, (3) differences in BP will be detectable in the first few hours of life.
METHODS

Subjects
Clinical and demographic data concerning 473 preterm, inborn infants weighing 500 to 1499 gm were extracted from the National Institute of Child Health and Human Development Neonatal Research Network Database. All infants were admitted consecutively over a 31-month period to the neonatal intensive care unit of the University of Cincinnati Medical Center. Data were collected according to standardized definitions for each item by Network research nurses and were validated by independent review. Infants with major malformations were excluded. Corticosteroid treatment of subjects was deter-
mined by attending obstetricians in accordance with clinical needs (e.g., anticipation of preterm delivery). Data were collected before widespread implementation of the National Institutes of Health (NIH) Consensus Conference on antenatal corticosteroids. 10 A complete course of corticosteroids was defined as two doses of dexamethasone 12 hours apart, given at least 24 hours but no more than 7 days before delivery. A course of corticosteroids was considered partial when only one dose of dexamethasone was given before delivery. Because the effects of steroids on BP may occur in Ͻ24 hours, 6 we considered all infants born to mothers who received a corticosteroid course, either complete or partial. A total of infants were born to mothers treated with dexamethasone before delivery; these infants represented the study group. Among the 393 infants born to mothers who did not receive corticosteroids, 100 were selected as controls by assignment of random numbers. Of these, two infants were subsequently excluded, due to an insufficient number of BP measurements, leaving 98 infants in the control population. Infants were stratified by birth weight into two categories: 500 to 999 gm and 1000 to 1499 gm.
BP Measurements
The mean arterial BP values obtained by the bedside nurse at the time of admission to the neonatal intensive care unit and at 3, 6, 12, 18, and 24 hours of life were extracted from the infants' medical records. BP measurements were taken when infants were in a quiet, inactive state, as part of routine clinical care. Values were recorded three or more times for all infants. In infants with indwelling umbilical or peripheral arterial catheters, BP was measured directly by a Siemens Sirecust Model 404 System Monitor (Siemens Medical Systems, Erlangen, Germany). In infants without an arterial catheter, BP was measured noninvasively by the oscillometric technique with a Dinamap monitor (Critikon Inc., Tampa, FL). Either the upper arm or calf was used, depending on the location of intravenous sites. Cuff size was selected according to limb size (cuff width to limb circumference ratio of Ͼ0.44).
11 The first BP determination was discarded, according to the manufacturer's recommendation. In our institution, no differences were found between arm and calf BP in the first 5 days of life. 12 Consequently, either site was used in clinical practice. Previous studies [13] [14] [15] [16] [17] have demonstrated similar BP results with either the oscillometric or intra-arterial method: therefore, we combined all BP data for our analyses.
We did not include every perinatal variable in the analysis. Only known potential confounding factors that may influence BP, such as birth weight and gestational age, 13,18 -20 sex, 20 Apgar scores, 17 need for mechanical ventilation, 17, 21 and presence of either pregnancy-induced or chronic maternal hypertension, 17, 22 were recorded. Details of use of vasopressors (epinephrine, dopamine, or dobutamine) and of volume expansion (total amount of all volume expanders administered over the first 24 hours, including volume support in the delivery room) were also recorded. Although there is no formal protocol on BP support in our neonatal intensive care unit, the general practice is to maintain the mean BP at ϳ30 mm Hg. 18 Volume expanders were given on clinical grounds only in the delivery room. From admission onwards, both vasopressors and volume expanders were administered based on BP values. There were no variations in clinical care during the study period.
Statistical Analysis
Data were analyzed using Statistical Analytical Systems Software (SAS) (SAS Institute, Cary, NC). Differences in mean BP between treated and untreated infants were compared by Student's t-test and repeated measures analysis. Apgar scores were not normally distributed and were, therefore, analyzed by Wilcoxon's rank sum test.
Stepwise regression was used to assess the relationship between steroid use as the independent variable and mean BP as the dependent (response) variable, after controlling for potentially confounding factors.
The following confounding variables were considered: birth weight, gestational age, sex, Apgar scores, need for mechanical ventilation, use of vasopressors and plasma expanders, and the method of BP measurement (direct intra-arterial or oscillometric). Data were expressed as mean Ϯ SD. Differences were judged significant at a p value of Ͻ0.05.
RESULTS
Selected demographic and clinical data are shown in Table 1 . There were no differences between groups with regard to birth weight, gestational age, sex, race, frequency of maternal hypertension, 1-minute Apgar score, need for mechanical ventilation, and frequency of all grades of intraventricular hemorrhage (IVH), severe IVH (grade 4), and cystic periventricular leukomalacia. Although not statistically significant ( p ϭ 0.19), the proportion of infants with grade 4 IVH among steroid-treated infants was 50% less than in controls (6% versus 12%). The 5-minute Apgar score was higher in steroid-treated infants than in controls ( p Ͻ 0.01). Steroid-treated infants received significantly less volume expanders (3.8 Ϯ 8.5 ml/kg versus 14.4 Ϯ 20.7 ml/kg; p ϭ 0.0001), and significantly fewer infants treated with steroids received vasopressor support (2% versus 11%; p ϭ 0.02) compared with controls. BP values were significantly higher in steroidtreated infants than in controls at all timepoints studied (Figure 1 ). Because we hypothesized that differences in BP would be more marked in the smallest infants, infants with birth weights of Ͻ1000 gm and Ն1000 gm were analyzed separately. In the subset of infants with birth weights of 500 to 999 gm, Apgar scores at 5 minutes were significantly higher in steroid-treated infants compared with controls (6.4 Ϯ 2.0 versus 4.8 Ϯ 2.4, respectively, p Ͻ 0.01). The difference in the rate of grade 4 IVH between steroid-treated infants and controls (11% versus 22%) did not reach statistical significance. Steroid-treated infants received significantly less volume expansion (6.7 Ϯ 11.1 ml/kg versus 24.7 Ϯ 23.9 ml/kg; p ϭ 0.0001), whereas there was no difference in vasopressor support (6% versus 21%; p ϭ 0.06). BP values were significantly higher in steroid-treated infants than in controls at all timepoints, except on admission, as shown in Figure 2 .
Of note, volume expanders were commonly given on admission to the neonatal intensive care unit, and controls received significantly more volume expanders than steroid-treated infants. Using mean BP as the dependent variable, the following independent variables were significant in stepwise regression: steroid group ( p ϭ 0.0001), 5-minute Apgar score ( p ϭ 0.0001), birth weight ( p ϭ 0.002), and mechanical ventilation ( p ϭ 0.01). By stepwise regression analysis, the method of BP measurement (direct intra-arterial versus oscillometric) was not significantly correlated with BP. BP differences between steroid-treated infants and controls remained significant after controlling for Apgar scores and mechanical ventilation.
Demographic and clinical data in the subgroup of infants with birth weights between 1000 and 1499 gm were also analyzed separately. Mechanical ventilation was used less frequently in steroidtreated infants than in controls (27% or 12 of 47 infants versus 47% or 25 of 53 infants, respectively; p ϭ 0.03). Steroid-treated infants also received less volume expansion (1.1 Ϯ 4.9 ml/kg versus 5.7 Ϯ 12.0 ml/kg; p ϭ 0.01). There was no significant difference in vasopressor support (0% versus 4%). BP values were significantly higher in steroid-treated infants than in controls at all timepoints, except at 12 hours of life (Figure 3 ). Using mean BP as the dependent variable, the following independent variables were significant in stepwise analysis: steroid group ( p ϭ 0.0001) and mechanical ventilation ( p ϭ 0.0001). The method of BP measurement (direct versus oscillometric) was not significant.
DISCUSSION
In this study, we demonstrate that antenatal administration of corticosteroids is associated with significantly higher mean arterial BPs and a decreased need for volume expansion and vasopressor support in infants weighing Ͻ1500 gm. This difference was significant both in the smallest infants (with birth weights between 500 to 999 gm) and, with the exception of vasopressor support, in infants with birth weights between 1000 and 1499 gm. Moreover, BP differences were already present on admission. Infants in these weight ranges often manifest hypotension requiring vasopressors and/or volume expansion. Low mean BP and volume expansion have been associated with an increased risk for IVH. [23] [24] [25] Therapies to ameliorate hypotension or reduce the need for volume expansion, therefore, may be critical to long-term outcome. Such therapies require an understanding of the mechanisms regulating vascular volume and tone in the preterm infant during transition to postnatal life. These mechanisms are complex and multifactorial. In sick preterm infants, a Յ30% expansion of plasma volume, for example, may have little or no effect on systemic BP. 26 Considerable evidence implicates the pituitary-adrenal axis and glucocorticoids as regulators of systemic BP in the preterm infant. [27] [28] [29] [30] [31] [32] Glucocorticoids influence BP through several mechanisms: (1) increasing plasma and extracellular fluid by shifting fluid from the intracellular compartment, 29, 30 (2) inducing the synthesis of angiotensinogen in hepatic cells, 33 (3) inhibiting the synthesis of vasodilator prostaglandins, 34, 35 (4) increasing vascular responsiveness to ␣ adrenergic amines, 36, 37 and (5) inhibiting nitric oxide production. 38 Preterm infants with hypotension that is resistant to vasopressors and volume expanders respond to relatively small doses of hydrocortisone. 5 Neonatal adrenal insufficiency in ill preterm infants is a transient phenomenon, because infants subsequently demonstrate normal adrenal function. 4 Three retrospective studies have evaluated the effect of antenatal corticosteroids on neonatal BP. 9, 39, 40 Leviton et al., 39 in a study on the effect of phenobarbital on IVH, found that the risk of developing subependymal hemorrhage was lower in infants exposed to antenatal steroids than in controls; however, these researchers did not find differences in the rate of hypotension (mean BP of Ͻ30 mm Hg). Gar- land et al., 40 in a study on rescue surfactant therapy, found that the reduced risk of severe IVH in infants exposed to antenatal corticosteroids was associated with avoidance of hypotension and not with surfactant-induced improvement in respiratory status. Given the study design, only the rates of hypotensive newborns were reported, with no details given on BP values over time and on possible differences among different birth weight groups. Moise et al. 9 showed that antenatal corticosteroids were associated with higher BPs and decreased need for BP support in preterm infants during the first 48 hours of life. However, their study was limited to infants with a gestational age of Յ27 weeks and did not include data on the administration of epinephrine or extra volume support in the delivery room as part of resuscitation procedures. In this study, there was no difference in neonatal BP before 16 hours of life. This is difficult to explain, because in extremely low birth weight infants the effect of dexamethasone on BP occurs 8 to 12 hours after a single dose. 6 Although the timing of steroid therapy was not stated in the study by Moise et al., a complete course is usually defined as two doses, 12 hours apart, given at least 24 hours but no more than 7 days before delivery. Even if all mothers received dexamethasone immediately before delivery, the effect should have been present well before 16 hours of life. This raises the question of possible unreported administration of volume and epinephrine in the delivery room. These details were not reported and could have masked earlier differences in BP between groups.
Differences in BP in the first hours of life may be important in very low birth weight infants. Hypotension, for example, is a known risk factor for IVH. 24 In infants with birth weights of 500 to 700 gm, 62% of IVHs occurred in the first 18 hours of life. 41 Of all the infants who developed IVH, 40% did so within the first 5 hours of life. 42 In addition, hypotension has an independent adverse effect on neonatal outcome at 24 months of age. 43 This study was not designed to assess the effect of antenatal corticosteroids on neonatal IVH, and we did not find a statistically significant difference in the rates of IVH. However, there were 50% fewer infants with grade 4 IVH in corticosteroid-treated infants compared with controls. At a 0.05 level of significance and 80% power, we would have needed 280 subjects in each group to demonstrate a statistical significance in this difference (6% versus 12%) in the whole population; a total of 140 subjects in each group would be needed for the difference (11% versus 22%) in the subset of infants weighing Ͻ1000 gm.
Our study has several limitations. First, more information regarding obstetrical complications might have been desirable to verify that the two groups were fully comparable. However, the list of perinatal variables is endless; trying to analyze all them would increase the possibility of obtaining a "chance" significance. We decided to record only variables already known to influence neonatal BP. By definition, this study design fails to identify potential new variables, unknown to affect BP. Second, our data were collected before widespread implementation of the NIH recommendations on antenatal corticosteroids. 10 This explains the very low rate of corticosteroid use in our hospital at that time and may limit the relevance of the study to current perinatal practice. Conversely, such studies would be more difficult to perform today, given the higher rate of corticosteroid use. In addition, our study confirms the effect of antenatal corticosteroids on neonatal BP and establishes that a significant effect is already detectable in the first hours of life and is not limited to the smallest infants. Finally, one may question the use of a mean BP value of Ͻ30 mm Hg as definition of neonatal hypotension. As stated in the methods, there was no institutional protocol on the treatment of hypotension. Use of volume expansion/vasopressors was at the discretion of the attending neonatologist on service. In the delivery room, it was based on clinical grounds (incomplete response to ventilation). From admission onwards, it was usually based on a mean BP value of Ͻ30 mm Hg. This may not be appropriate for all very low birth weight infants, as BP varies according to birth weight and age. However, BP ranges also vary among studies. In Zubrow's study, 44 the lower limit of normal for a 500-gm infant would be 28/11 mm Hg. However, Hegyi et al. 17 report much higher BP ranges in infants of 501 to 750 gm: 50 to 62 mm Hg (systolic) and 26 to 36 mm Hg (diastolic). Therefore, an unequivocal definition of hypotension in very low birth weight infants does not appear to exist at present. The focus of our paper, however, was not on neonatal hypotension and its treatment but on differences in mean BP between steroid-exposed infants and untreated controls. Attending neonatologists might have incorrectly diagnosed and treated neonatal hypotension, but there is no reason to suspect that they diagnosed differently between the two groups. Controls received significantly more volume expanders and vasopressors than steroidexposed infants, but, despite this, showed consistently lower mean BP values throughout the first 24 hours.
In summary, we conclude that: (1) antenatal steroids are associated with both a higher mean systemic BP and a decreased use of vasopressors and plasma volume expansion in very low birth weight infants during the first 24 hours of life; (2) the effect is not limited to the smallest infants, but is present also in infants with a birth weight between 1000 and 1499 gm; and (3) differences in BP are already significant in the first hours of life. We speculate that this finding may contribute to the mechanism of corticosteroid protection against conditions such as IVH.
